Skye Bioscience, Inc. Common Stock (SKYE)

PHARMACEUTICAL PREPARATIONS

Skye Bioscience, Inc. Common Stock (SKYE) is listed on Nasdaq, where it has traded since February 24, 2014.

Listed On
Nasdaq
Listed Since
February 24, 2014
Employees
12
Market Cap
$7M

About Skye Bioscience, Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 41 institutions reported holding SKYE, with 16.0 million shares worth $11.1 million in aggregate. The largest reported holder was 5am Venture Management, with 9.7 million shares worth $6.7 million. Of the 5 largest holders listed below, 1 reduced its position and 4 held their positions unchanged during the quarter.

InstitutionSharesValueQuarter change
5am Venture Management9,681,763$7MUnchanged
Versant Venture Management2,007,704$1MUnchanged
Baker Bros. Advisors1,575,243$1MUnchanged
Vanguard872,668$605KReduced 0.07%
Sphera Funds Management Ltd678,928$471KUnchanged

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is SKYE?

Skye Bioscience, Inc. Common Stock (SKYE) is listed on Nasdaq, where it has traded since February 24, 2014.

Who are the largest institutional holders of SKYE?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of SKYE were 5am Venture Management, Versant Venture Management and Baker Bros. Advisors.

How many institutions own SKYE?

41 institutions reported a position in SKYE for the quarter ended June 30, 2026, worth $11.1 million in total.

Did institutions buy or sell SKYE last quarter?

Of the 5 largest reported holders, 1 reduced its position and 4 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for SKYE.

Every reported institutional holder, plus insider and congressional trades in SKYE, on SentiSense.